Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis

Malashenkova I.K.

National Research Center «Kurchatov Institute», Moscow

Hailov N.A.

National Research Center «Kurchatov Institute», Moscow

Krynskiy S.A.

National Research Center «Kurchatov Institute», Moscow

Ogurtsov D.P.

National Research Center «Kurchatov Institute»;
Federal and Clinical Center of PhysicalCchemical Medicine Russia

Kazanova G.V.

National Research Center «Kurchatov Institute», Moscow

Velichkovckiy B.B.

National Research Center «Kurchatov Institute», Moscow

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Center

Ponomareva E.V.

Mental Health Research Center

Kolykhalov I.V.

Mental Health Research Center

ORCID: 0000-0002-2358-1579

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Didkovsky N.A.

Research Institute of physical-chemical medicine, Moscow

Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis

Authors:

Malashenkova I.K., Hailov N.A., Krynskiy S.A., Ogurtsov D.P., Kazanova G.V., Velichkovckiy B.B., Selezneva N.D., Fedorova Ya.B., Ponomareva E.V., Kolykhalov I.V., Gavrilova S.I., Didkovsky N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3): 39‑43

DOI: 10.17116/jnevro20161163139-43

Downloaded: 17

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Malashenkova IK, Hailov NA, Krynskiy SA, et al. . Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):39‑43. (In Russ.)
https://doi.org/10.17116/jnevro20161163139-43

Close metadata

Recommended articles:

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

The role of astrocytes, circadian rhythms and light pollution in the pathogenesis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):20-25

Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):81-91

Experience of using the combined drug Mioreol in patients with Alzheimer’s disease and mixed dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):34-43

Regulation of mitophagy and mitochondrial biogenesis by monocarbonyl analogues of curcumin in the cerebral cortex of rats in experimental Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):109-114

Objective — to evaluate the levels of cytokines (IFNα, IFNγ, IL-2, Il-4, IL-6, IL-8, IL-10, IL-12, IL-15), IL-1β receptor antagonist (IL-1RA), vascular endothelial growth factor (VEGF) and its antagonist, the soluble form of receptor 1 (sVEGFR1) in the blood serum of patients with Alzheimer’s disease, with early onset (ADEO) and late onset (ADLO), and in patients with mild cognitive impairment (MCI).

Material and methods. Levels of interleukins, IL-1RA, VEGF and sVEGFR1 were measured in 20 patients with AD and 11 patients with MCI using ELISA. These parameters were compared to the severity of cognitive impairment assessed by the performance on neurocognitive tests.

Results and conclusion. The levels of key cytokines (IL-8, TNFα, IL-12), VEGF and sVEGFR1 as well as anti-inflammatory proteins were different in patients with ADEO, ADLO and MCI. These differences suggest the phenotypic and genotypic heterogeneity of the disease that demands further research.

Keywords:

Alzheimer’s disease

mild cognitive impairment (MCI)

inflammatory and anti-inflammatory cytokines

IL-1 receptor antagonist (IL-1RA)

vascular endothelial growth factor (VEGF)

soluble receptor 1 of VEGF (sVEGFR1)

Authors:

Malashenkova I.K.

National Research Center «Kurchatov Institute», Moscow

Hailov N.A.

National Research Center «Kurchatov Institute», Moscow

Krynskiy S.A.

National Research Center «Kurchatov Institute», Moscow

Ogurtsov D.P.

National Research Center «Kurchatov Institute»;
Federal and Clinical Center of PhysicalCchemical Medicine Russia

Kazanova G.V.

National Research Center «Kurchatov Institute», Moscow

Velichkovckiy B.B.

National Research Center «Kurchatov Institute», Moscow

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Center

Ponomareva E.V.

Mental Health Research Center

Kolykhalov I.V.

Mental Health Research Center

ORCID: 0000-0002-2358-1579

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Didkovsky N.A.

Research Institute of physical-chemical medicine, Moscow

List of references:

Jeffrey L Cummings, Bruce L et al. Creativity and Dementia: Emerging Diagnostic and Treatment Methods for Alzheimer’s Disease. Primary Psychiatry. 2008;15:2(suppl 1):1-24.
Li X, Zhang ZJ. Neuropsychological and Neuroimaging Characteristics of Amnestic Mild Cognitive Impairment Subtypes: A Selective Overview. CNS Neurosci Ther. 2015. doi: 10.1111/cns.12391.
Meraz-Ríos MA, Franco-Bocanegra D, Toral Rios D, Campos-Peña V. Early onset Alzheimer's disease and oxidative stress. Oxid Med Cell Longev. 2014;2014:375968. doi: 10.1155/2014/375968.
Zou Z, Liu C, Che C, Huang H. Clinical genetics of Alzheimer's disease. Biomed Res Int. 2014;2014:291862. doi: 10.1155/2014/291862.
Kljushnik TP, Androsova LV, Dupin AM. Vrozhdennyj immunitet i bolezn' Al'cgejmera. Psihiatrija. 2011;1:52-58. (In Russ.).
Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014;50(2):534-544. doi: 10.1007/s12035-014-8657-1.
Lueg G, Gross CC, Lohmann H. et al.Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2015;36(1):81-89. doi: 10.1016/j.neurobiolaging.2014.08.008.
Masera RG, Prolo P, Sartori ML et al. Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease. Psychoneuroendocrinology. 2002;27(4):447-461. doi: 10.1016/s0306-4530(01)00062-2.
Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid â for Alzheimer's disease pathogenesis. J Neuroinflammation. 2014;11:48. doi: 10.1186/1742-2094-11-48.
Kuhla A, Ludwig SC, Kuhla B et al. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain. Neurobiol Aging. 2015;36(2):753-761. doi: 10.1016/j.neurobiolaging.2014.09.025.
Zilka N, Kazmerova Z, Jadhav S et al. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012;9:47. doi: 10.1186/1742-2094-9-47.
Buerger S, Noack M, Kirazov LP et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci. 2009;27(6):517-523. doi: 10.1016/j.ijdevneu.2009.06.011.
Hohman TJ, Bell SP, Jefferson AL. The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline: Exploring Interactions With Biomarkers of Alzheimer Disease. JAMA Neurol. 2015;72(5):520-529. doi: 10.1001/jamaneurol.2014.4761.
Klettner A, Roider J. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefes Arch Clin Exp Ophthalmol. 2009;247(11):1487-1492. doi: 10.1007/s00417-009-1139-x.
Schafer G, Cramer T, Suske G et al. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem. 2003;278(10):8190-8198. doi: 10.1074/jbc.m211999200.
Wu FT, Stefanini MO, Mac Gabhann F et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14(3):528-552. doi: 10.1111/j.1582-4934.2009.00941.x.
Yang SP, Kwon BO, Gho YS, Chae CB. Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. J Neurochem. 2005;93(1):118-127. doi: 10.1111/j.1471-4159.2004.02993.x.
Motta M, Imbesi R, Di Rosa M et al. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett. 2007;114(1):46-51. doi: 10.1016/j.imlet.2007.09.002.
McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer`s disease. Neurology. 1984;146:939-944. doi: 10.1212/wnl.34.7.939.
Petersen RC, Touchon J. Consensus on mild cognitive impairment. Research and Practice in Alzheimer’s Disease, E.A.D.C./A.D.C.S. Joint Meeting (Serdi Publisher, Paris). 2005;10:24-32.
Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans. 2004;32(1):144-146. doi: 10.1042/bst0320144.
Menachem-Zidon BO, Avital A, Ben-Menahem Y et al. Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling. Brain Behav Immun. 2011;25(5):1008-1016. doi: 10.1016/j.bbi.2010.11.007.
Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015;3(10):136. doi:10.3978/ j.issn.2305-5839.2015.03.49.
Belkhelfa M, Rafa H, Medjeber O et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res. 2014;34(11):839-847. doi: 10.1089/jir.2013.0085.
Stoeck K, Schmitz M, Ebert E et al. Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. J Neuroinflammation. 2014;11:170. doi: 10.1186/s12974-014-0170-y.
Zhu XC, Tan L, Jiang T et al. Association of IL-12A and IL-12B polymorphisms with Alzheimer's disease susceptibility in a Han Chinese population. J Neuroimmunol. 2014;274(1-2):180-184. doi: 10.1016/j.jneuroim.2014.06.026.
Malashenkova IK, Kazanova GV, Didkovskij NA. Interlejkin-15: stroenie, signaling i rol' v immunnoj zashhite. Molekuljarnaja medicina. 2014;3:9-20. (In Russ.).

Close metadata